...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of neurology >BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis.
【24h】

BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis.

机译：在多发性硬化症患者中，BG-12可以将新的增强型病变向T1型低水平病变的发展减少。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BG-12, an immunomodulatory agent, reduces frequency of new gadolinium-enhancing (Gd+) lesions in relapsing multiple sclerosis (MS). This study reports the effect of 240 mg BG-12 orally three times daily (tid) for 24 weeks on the evolution of new Gd+ lesions to T1-hypointense lesions. Brain magnetic resonance imaging (MRI) scans from patients in placebo and 240 mg BG-12 tid arms of a phase 2b study were examined retrospectively. Included patients had at least one new Gd+ lesion from weeks 4 to 12. Week 24 scans were analyzed for number and proportion of new Gd+ lesions that evolved to T1-hypointense lesions. Eighteen patients receiving BG-12 and 38 patients receiving placebo were included in the analysis. The analysis tracked 147 new Gd+ lesions in patients from the BG-12 group and 221 Gd+ lesions in patients from the placebo group. The percentage of Gd+ lesions that evolved to T1-hypointense lesions was 34% lower with BG-12 treatment versus placebo (29%, BG-12; 44%, placebo; odds ratio 0.51; 95% confidence interval 0.43, 0.61; p < 0.0001). In addition to reducing frequency of new Gd+ lesions, BG-12 significantly reduced probability of their evolution to T1-hypointense lesions in patients with MS compared with placebo.
机译：BG-12是一种免疫调节剂，可降低复发性多发性硬化症（MS）中新的增强ado（Gd +）病变的频率。这项研究报告了240 mg BG-12口服，每天3次（每日两次），持续24周，对新的Gd +病变向T1低点病变的演变产生影响。回顾性研究了一项2b期研究的安慰剂和240 mg BG-12 tid臂患者的脑磁共振成像（MRI）扫描。纳入的患者从第4周到第12周至少有一个新的Gd +病变。分析了第24周的扫描，分析了新的Gd +病变演变为T1低点性病变的数量和比例。分析包括18例接受BG-12的患者和38例接受安慰剂的患者。该分析追踪了BG-12组患者的147个新Gd +病变和安慰剂组患者的221个Gd +病变。与安慰剂相比，BG-12治疗使Gd +病变演变为T1低点性病变的百分比降低了34％（29％，BG-12; 44％，安慰剂;比值比为0.51; 95％置信区间为0.43，0.61; p < 0.0001）。与安慰剂相比，除了减少新的Gd +病变的发生频率外，BG-12还显着降低了MS患者演变为T1低氧性病变的可能性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号